LA JOLLA PHARMACEUTICAL CO
DelistedCIK 920465fmd_07HG64Z3B7BKRR36FT6PJJHBXRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Jun 30, 2022, 49 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 1 | 1 | 0 | 10 | 23 | 33 | 76 |
| Cost of revenue | – | – | – | – | 0 | 0 | 1 | 2 | 8 | – |
| Net interest income | – | – | – | – | – | – | (4) | (7) | (4) | (2) |
| Gross profit | – | – | – | – | 1 | 0 | 9 | 21 | 26 | – |
| Research and development | 1 | 4 | 10 | 29 | 62 | 85 | 43 | 85 | 23 | 5 |
| Selling, general and administrative | – | – | – | – | 17 | 31 | 24 | 45 | 38 | 35 |
| Operating income | (11) | (18) | (21) | (42) | (78) | (115) | (58) | (110) | (36) | 22 |
| Interest expense | – | – | – | – | 0 | 0 | 7 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | – | (0) | 1 |
| Income before taxes | – | – | – | – | – | – | – | – | (39) | 20 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (39) | 20 |
| Net income | (8) | (18) | (21) | (42) | (78) | (115) | (62) | (117) | (39) | 20 |
| Net income to common shareholders | (9) | (19) | (21) | (42) | (78) | (115) | – | – | – | – |